The new name and branding come after a three-year series of strategic acquisitions.
International biopharmaceutical services provide, CATO SMS has rebranded and became Allucent to aid in bringing advanced therapies to light.
The latest move is aimed at underscoring the company’s spotlight on meeting the specified requirements of small and mid-sized biotech firms.
The new name and branding come after a three-year series of strategic takeovers of Array Biostatistics, Nuventra and clinical research provider Pharm-Olam.
These acquisitions doubled the size of the company, boosted and extended its expertise and enlarged its reach globally.
With over three decades of experience, Allucent is now a unified organisation intended for backing small and mid-sized biotech firms in achieving breakthrough science.
Established to address this requirement, the company provides full-service clinical trial expertise, deep treatment capabilities, product development and consultation services.
Allucent chairman and CEO Mark Goldberg said: “In three short years, we’ve transformed our company to meet the unique needs of small and mid-sized biotechs.
“Our new name, Allucent, puts the focus on the clients we exist to serve and aligns our people under our shared passion of helping to bring new therapies to light.
“As we continue our growth journey, we’re committed to making sure we remain big enough to deliver but small enough to care.”
Allucent will leverage deep capabilities and a high-touch collaboration model to provide various services and therapeutic expertise for biotech firms including flexible clinical and regulatory solutions and a team of international consultants.
It also has strong scientific and drug development capabilities, a worldwide workforce of over 1,200 staff and broader coverage geographically in more than 60 countries.
In March this year, CATO SMS was engaged as GeoVax Labs’ clinical research organisation partner to handle two Phase II trials of its Covid-19 vaccine candidate, GEO-CM04S1.
